HLB bioStep
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB bioStep runs preclinical contract research, meaning it tests drug candidates on laboratory animals on behalf of pharmaceutical and biotech companies before those drugs enter human trials.
Its customers include pharmaceutical firms, biotech ventures, research institutes, and universities listed on KOSDAQ, Korea's tech and small-cap exchange. The company's core service is efficacy testing, confirming whether a drug candidate actually works, and it also designs and builds animal-laboratory facilities and supplies lab consumables to clients.
Summary is AI-generated and may contain errors · figures from DART filings
HLB bioStep expanded its toxicology capabilities by acquiring HLB BioCode (formerly Croen) as a subsidiary, adding regulated GLP-standard toxicity testing to its existing non-GLP preclinical services.
HLB bioStep in five facts
What does HLB bioStep do?
HLB bioStep runs preclinical contract research, meaning it tests drug candidates on laboratory animals on behalf of pharmaceutical and biotech companies before those drugs enter human trials.
Where is HLB bioStep listed and in which sector?
HLB bioStep (Korean name: HLB바이오스텝) trades under KRX code 278650 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Biotechnology.
How large is HLB bioStep?
Its market capitalisation was US$79.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB bioStep's latest annual revenue and operating profit?
For fiscal year 2025, HLB bioStep reported revenue of US$55.9M, an operating loss of US$6.5M and a net loss of US$15.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 27.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 13
- Investor relations (IR) meetingOct 12
- Material event report (decision to redeem own convertible bonds early)
HLB bioStep Co., Ltd. decided on September 3, 2026 to redeem before maturity US$1.48M face amount of its 4th-series convertible bonds from related-party seller HLB Genex Co., Ltd., paying US$1.52M (principal plus interest) with payment scheduled for September 11, 2026, using own funds; after redemption US$1.48M of the bonds' face amount remains outstanding.
Capital raise · Sep 3 - Material event report (decision to redeem own convertible bonds early)
HLB bioStep Co., Ltd. decided on July 21, 2026 to redeem US$4.05M in face value of its 4th-round privately placed convertible bonds before maturity after bondholders exercised their put option, for a total acquisition amount of US$4.18M including principal and interest.
Capital raise · Jul 21 - Material event report (decision to redeem own convertible bonds early)
HLB bioStep Co., Ltd. decided on July 14, 2026 to redeem US$6.55M face value of its Series 4 private convertible bonds (issued February 20, 2025, maturing February 20, 2028) before maturity for a total of US$6.75M (principal plus interest) paid in two installments on July 14 and August 13, 2026, leaving US$6.72M outstanding; the bonds were sold by HLB Life Science Co., Ltd. (a related party of the largest shareholder) and 20 other bondholders.
Capital raise · Jul 14 - Trading suspension (share consolidation/split registration)M&A · Apr 21
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB bioStep updated its previously filed consolidated results for FY2025: revenue of US$50.3M (+27.3% year on year), an operating loss of US$5.85M and a net loss of US$13.8M.
Earnings · Mar 11 · 2 versions - Treasury share disposal: results reportTreasury Shares · Mar 4
- Material event report (treasury share disposal)Treasury Shares · Feb 2